accountcausing regulators to extend a review of the drug by three months. The company also announced it fired Chief Financial Officer Hayden. Savient shares dove $1.85, or 25.3 percent, to $5.45 in morning trading. The stock has ranged from $2.80 to $28.42 over...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Savient skids on gout drug delay and CFO change
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account